|
|
Volumn 176, Issue 1, 2017, Pages 131-132
|
|
Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma
|
|
Author keywords
hodgkin lymphoma; PD 1; pembrolizumab; refractory
|
|
Indexed keywords
BLEOMYCIN;
BRENTUXIMAB VEDOTIN;
CISPLATIN;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DACARBAZINE;
DEXAMETHASONE;
DOXORUBICIN;
ETOPOSIDE;
GEMCITABINE;
NIVOLUMAB;
PEMBROLIZUMAB;
PREDNISOLONE;
PROCARBAZINE;
VINBLASTINE;
VINCRISTINE;
IMMUNOLOGICAL ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
ADULT;
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GROWTH;
CANCER RECURRENCE;
CANCER REGRESSION;
CANCER STAGING;
CASE REPORT;
CLASSICAL HODGKIN LYMPHOMA;
CONTROLLED STUDY;
DISEASE EXACERBATION;
DRUG COST;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG MEGADOSE;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
HUMAN;
LETTER;
LOW DRUG DOSE;
MALE;
MONOTHERAPY;
MULTIPLE CYCLE TREATMENT;
NAMED GROUPS OF PERSONS;
NODULAR SCLEROSIS HODGKIN LYMPHOMA;
PHASE 1 CLINICAL TRIAL;
PNEUMONIA;
PORTUGUESE (CITIZEN);
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
REFRACTORY CLASSICAL HODGKIN LYMPHOMA;
TREATMENT DURATION;
TREATMENT FAILURE;
TREATMENT RESPONSE;
UKRAINIAN;
UNSPECIFIED SIDE EFFECT;
YOUNG ADULT;
FEMALE;
HODGKIN DISEASE;
PATHOLOGY;
TUMOR RECURRENCE;
ADULT;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;
DISEASE PROGRESSION;
FEMALE;
HODGKIN DISEASE;
HUMANS;
MALE;
NEOPLASM RECURRENCE, LOCAL;
YOUNG ADULT;
|
|
EID: 85006745134
PISSN: 00071048
EISSN: 13652141
Source Type: Journal
DOI: 10.1111/bjh.13920 Document Type: Letter |
|
Times cited : (13)
|
|
References (3)
|
